{
  "abstract": "The renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) recognises the condition’s broader endocrine and metabolic aspects.1 These include insulin resistance, androgen excess, and increased risks of diabetes and cardiovascular disease.",
  "authors": [
    {
      "affiliations": [
        "Department of Primary Care and Public Health, Imperial College London, London, UK"
      ],
      "name": "Azeem Majeed"
    }
  ],
  "title": "PCOS name change to PMOS: clinical coding systems will take a while to catch up",
  "uid": "67e0b71a-f36d-505e-8fc0-4be03e1b2287"
}